Table 2.

Demographic, disease, and treatment characteristics

Characteristics	Very-high-risk (N=99)	Other NCCN high-risk (N=189)	P-value
Median age (range), yrs	65 (44–79)	69 (48–83)	0.002
Africa-American race, %	34.3	23.3	0.05
Initial PSA in ng/mL, %			0.001
<10	27.3	38.6
10–20	13.1	23.8
>20	59.6	37.6
Gleason sum, %			<0.001
3+3	9.1	36.0
3+4	9.1	23.8
4+3	7.4	8.1
4+4	37.4	18.5
4+5	16.2	14.3
5+4	14.1	---
5+5	6.1	---
T-stage, %			<0.001
T1	5.1	21.2
T2	28.3	48.7
T3/T4	66.7	30.2
Perineural invasion on biopsy, %	43.4	31.2	0.04
Biopsy cores
Median number of sampled cores (range)	10 (4–17)	8 (4–16)	0.54
Median number of positive cores (range)	5 (1–14)	3 (1–12)	0.01
Median percentage of positive cores (range)	67 (8–100)	45 (8–100)	<0.001
Median radiation dose (range), Gy	70.2 (64.8–75.6)	70.2 (66.6–75.6)	0.81
Intensity modulated radiation therapy, %	22.2	15.9	0.18
Median duration of ADT (range), months	28 (0–40)	28 (0–52)	0.11
None	8.1	16.6	0.05
Neoadjuvant and concurrent only	16.2	22.2	0.04
Neoadjuvant, concurrent, and adjuvant	75.8	61.4	0.01

Abbreviations: National Comprehensive Care Network (NCCN); prostate-specific antigen (PSA); androgen deprivation therapy (ADT)